CN104349788B - 新的疏水蛋白释放系统 - Google Patents

新的疏水蛋白释放系统 Download PDF

Info

Publication number
CN104349788B
CN104349788B CN201380028007.8A CN201380028007A CN104349788B CN 104349788 B CN104349788 B CN 104349788B CN 201380028007 A CN201380028007 A CN 201380028007A CN 104349788 B CN104349788 B CN 104349788B
Authority
CN
China
Prior art keywords
acid amides
protein
hgh
amides
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380028007.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104349788A (zh
Inventor
M·坎皮西
C·古丽瑟
D·雷尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Pharmaceutical Co Ltd
Original Assignee
Fidia Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Pharmaceutical Co Ltd filed Critical Fidia Pharmaceutical Co Ltd
Publication of CN104349788A publication Critical patent/CN104349788A/zh
Application granted granted Critical
Publication of CN104349788B publication Critical patent/CN104349788B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201380028007.8A 2012-05-31 2013-05-30 新的疏水蛋白释放系统 Active CN104349788B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000173A ITPD20120173A1 (it) 2012-05-31 2012-05-31 "nuovo sistema di rilascio di proteine idrofobiche"
ITPD2012A000173 2012-05-31
PCT/IB2013/054477 WO2013179258A1 (en) 2012-05-31 2013-05-30 New release system of hydrophobic proteins

Publications (2)

Publication Number Publication Date
CN104349788A CN104349788A (zh) 2015-02-11
CN104349788B true CN104349788B (zh) 2017-07-28

Family

ID=46321311

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028007.8A Active CN104349788B (zh) 2012-05-31 2013-05-30 新的疏水蛋白释放系统

Country Status (13)

Country Link
US (1) US9731019B2 (enExample)
EP (1) EP2854830B1 (enExample)
JP (1) JP6247687B2 (enExample)
KR (1) KR102090551B1 (enExample)
CN (1) CN104349788B (enExample)
CA (1) CA2874958C (enExample)
EA (1) EA031390B1 (enExample)
ES (1) ES2885764T3 (enExample)
IN (1) IN2014KN02739A (enExample)
IT (1) ITPD20120173A1 (enExample)
MX (1) MX357799B (enExample)
PT (1) PT2854830T (enExample)
WO (1) WO2013179258A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900003887A1 (it) 2019-03-18 2020-09-18 Fidia Farm Spa Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione
IT201900009933A1 (it) * 2019-06-24 2020-12-24 Fidia Farm Spa Composizioni farmaceutiche comprendenti derivati ammidici dell'acido ialuronico per uso nel trattamento di traumi ossei, in particolare in pazienti con problemi di osteopenia o osteoporosi
IT202300027378A1 (it) * 2023-12-20 2025-06-20 Fidia Farm Spa Sistema di rilascio per la somministrazione topica o intrarticolare di farmaci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589036A1 (en) * 1998-07-06 2005-10-26 Fidia Farmaceutici S.p.A. Amides of hyaluronic acid and the derivatives thereof
WO2006092233A1 (en) * 2005-03-02 2006-09-08 Fidia Farmaceutici S.P.A. Amide derivatives of hyaluronic acid in osteoarthrosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US495774A (en) 1893-04-18 Island
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
IT1306679B1 (it) 1999-06-29 2001-10-02 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico per la preparazione dicomposizoni farmaceutiche e biomateriali per la prevenzione della
US6645485B2 (en) 2000-05-10 2003-11-11 Allan R. Dunn Method of treating inflammation in the joints of a body
US20080220053A1 (en) * 2004-12-14 2008-09-11 Fidia Advanced Biopolymers S.R.L. Process for the Preparation of Two and Three Dimensional Polymer Scaffolds
MY139088A (en) 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
ITPD20050207A1 (it) * 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
IT1402385B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589036A1 (en) * 1998-07-06 2005-10-26 Fidia Farmaceutici S.p.A. Amides of hyaluronic acid and the derivatives thereof
WO2006092233A1 (en) * 2005-03-02 2006-09-08 Fidia Farmaceutici S.P.A. Amide derivatives of hyaluronic acid in osteoarthrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Effect of hyaluronic acid amide derivative on equine synovial fluid viscoelasticity;Borzacchiello et al.;《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH》;20100331;第92A卷(第3期);全文 *

Also Published As

Publication number Publication date
MX2014014536A (es) 2015-02-24
JP2015518042A (ja) 2015-06-25
EP2854830A1 (en) 2015-04-08
KR102090551B1 (ko) 2020-03-19
US20150290326A1 (en) 2015-10-15
US9731019B2 (en) 2017-08-15
KR20150016951A (ko) 2015-02-13
CA2874958C (en) 2023-02-14
EA031390B1 (ru) 2018-12-28
PT2854830T (pt) 2021-09-02
ES2885764T3 (es) 2021-12-15
IN2014KN02739A (enExample) 2015-05-08
CN104349788A (zh) 2015-02-11
EA201491991A1 (ru) 2015-03-31
MX357799B (es) 2018-07-25
CA2874958A1 (en) 2013-12-05
HK1206993A1 (en) 2016-01-22
JP6247687B2 (ja) 2017-12-13
ITPD20120173A1 (it) 2013-12-01
WO2013179258A1 (en) 2013-12-05
EP2854830B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
US9561260B2 (en) Compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid
KR101233564B1 (ko) 가교 다당 미립자 및 그 제조 방법
KR100577041B1 (ko) 서방성제형
US8524662B2 (en) Compositions and methods for treating joints
EP2086567B1 (en) Sustained release formulations comprising very low molecular weight polymers
KR20090013179A (ko) 이관능화된 다당류
CN1230108A (zh) 用于持续释放蛋白质药物的温敏凝胶
CN101511380A (zh) 用于持续释放递送肽的药物组合物
KR102088107B1 (ko) 염증 억제 펩타이드의 물리적/화학적 함유 주사 제형 전달체, 이의 제조 방법 및 응용
US20190119486A1 (en) Hyaluronic acid conjugates and uses thereof
JP2015057384A (ja) 薬学的使用のための新規のニュールツリン複合体
CN104349788B (zh) 新的疏水蛋白释放系统
EP2272875B1 (en) Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
US11951176B2 (en) Stabilization of glucagon by trehalose glycopolymer nanogels
HK1206993B (en) New release system of hydrophobic proteins
CN116440284A (zh) 一种蛋白质-含葡萄糖聚合物的偶联物及其制备方法及应用
KR20080041661A (ko) 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206993

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1206993

Country of ref document: HK